Search

Displaying results 5501 - 5510 of 7181 in total
  1. Drug

    Dithioerythritol

    go.drugbank.com/drugs/DB01692
    Experimental

    A compound that, along with its isomer, Cleland's reagent (dithiothreitol), is used for the protection of sulfhydryl groups against oxidation to disulfides and for the reduction of disulfides to sulfhydryl

  2. Drug

    2'-C-methylcytidine

    go.drugbank.com/drugs/DB13921
    Experimental

    Upon phosphorylation into its 5-triphosphate form, this metabolite inhibits viral RNA chain elongation and viral RNA-dependent RNA polymerase activity.

  3. Drug

    Danegaptide

    go.drugbank.com/drugs/DB11821
    Investigational

    Danegaptide has been investigated for the treatment of Focus of Study is STEMI.

  4. Drug

    3-Fluoro-L-tyrosine

    go.drugbank.com/drugs/DB04436
    Experimental

    This compound belongs to the phenylpropanoic acids. … These are compounds whose structure contain a benzene ring conjugated to a propanoic acid. 3-Fluoro-L-tyrosine targets the protein superoxide dismutase [mn], mitochondrial.

  5. Drug

    PR-15

    go.drugbank.com/drugs/DB06037
    Investigational

    PR-15 is a novel anti-platelet protein with the potential to treat arterial thrombosis occurring during acute coronary syndromes without the bleeding risk associated with existing agents.

  6. Drug

    Piretanide

    go.drugbank.com/drugs/DB02925
    Approved

    Piretanide (INN, trade names Arelix, Eurelix, Tauliz) has been synthesized in 1973 at Hoechst AG (Germany) as a loop diuretic compound by using a then-new method for introducing cyclic amine residues in

  7. Drug

    Iodipamide

    go.drugbank.com/drugs/DB04711
    ApprovedWithdrawn

    Iodipamide is a water-soluble radiographic contrast media for cholecystography and intravenous cholangiography.

  8. Drug

    Alvespimycin

    go.drugbank.com/drugs/DB12442
    Investigational

    In comparison to the first HSP90 inhibitor tanespimycin, it exhibits some pharmacologically desirable properties such as reduced metabolic liability, lower plasma protein binding, increased water solubility

  9. Drug

    Pimicotinib

    go.drugbank.com/drugs/DB18972
    Investigational

    It was initially developed by Abbisko Therapeutics Co in collaboration with Merck KGaA. [L53748] Pimicotinib was granted Fast Track Designation in December 2023 by the FDA. [L53753]

    Synonyms: 1-Pyrrolidinecarboxamide, 3,3-dimethyl-N-[6-methyl-5-[[2-(1-methyl-1H-pyrazol-4-yl)-4-pyridinyl]oxy]-2-pyridinyl]-2-oxo-, 3,3-Dimethyl-N-[6-methyl-5-[[2-(1-methyl-1H-pyrazol-4-yl)-4-pyridinyl]oxy]-2-pyridinyl]-2-oxo-1-pyrrolidinecarboxamide
  10. Drug

    KP1237

    go.drugbank.com/drugs/DB18401
    Experimental

    KP1237 is a antibody-redirecting molecule composed of two binding sites (a CD38 binder and a universal antibody binding terminus binder) connected by a linker chain.